Advanced Solid Tumors Harboring the KRAS G12C Mutation Clinical Trials in Seoul

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments